MARKET

AMPH

AMPH

Amphastar Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

36.53
-0.19
-0.52%
Opening 13:33 05/26 EDT
OPEN
36.12
PREV CLOSE
36.72
HIGH
36.81
LOW
35.75
VOLUME
269.04K
TURNOVER
6.85M
52 WEEK HIGH
44.46
52 WEEK LOW
17.56
MARKET CAP
1.78B
P/E (TTM)
22.70
1D
5D
1M
3M
1Y
5Y
Amphastar Pharmaceuticals Secures FDA Approval for Regadenoson
MT Newswires · 2d ago
Insider Sell: Amphastar Pharmaceuticals
MT Newswires · 3d ago
Has Amphastar Pharmaceuticals (AMPH) Outpaced Other Medical Stocks This Year?
Here is how Amphastar Pharmaceuticals (AMPH) and Patterson Cos. (PDCO) have performed compared to their sector so far this year.
Zacks · 05/11 13:40
Amphastar Pharmaceuticals (AMPH) Q1 Earnings and Revenues Top Estimates
Amphastar (AMPH) delivered earnings and revenue surprises of 42.42% and 8.83%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/09 22:05
BRIEF-Amphastar Pharmaceuticals Q1 GAAP Earnings Per Share $0.47
reuters.com · 05/09 21:12
Amphastar Pharmaceuticals Non-GAAP EPS of $0.47, revenue of $120.4M
Amphastar Pharmaceuticals press release (NASDAQ:AMPH): Q1 Non-GAAP EPS of $0.47. Revenue of $120.4M (+16.9% Y/Y).
Seekingalpha · 05/09 21:00
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2022
4 Million for the Three Months Ended March 31, 2022RANCHO CUCAMONGA, CA / ACCESSWIRE / May 9, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") today reported results for the three months ended March 31, 2022.
ACCESSWIRE · 05/09 20:05
-- Earnings Flash (AMPH) AMPHASTAR PHARMACEUTICALS Reports Q1 EPS $0.47, vs. Street Est of $0.36
MT Newswires · 05/09 16:13
More
No Data
Learn about the latest financial forecast of AMPH. Analyze the recent business situations of Amphastar Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

16.67%Strong Buy
33.33%Buy
50.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average AMPH stock price target is 39.50 with a high estimate of 45.00 and a low estimate of 33.00.
High45.00
Average39.50
Low33.00
Current 36.53
EPS
Actual
Estimate
0.120.230.350.47
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 221
Institutional Holdings: 33.71M
% Owned: 69.04%
Shares Outstanding: 48.83M
TypeInstitutionsShares
Increased
61
1.34M
New
40
952.88K
Decreased
47
899.71K
Sold Out
7
38.33K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.26%
Pharmaceuticals & Medical Research
+0.38%
Key Executives
Chairman/Chief Operating Officer/Director
Mary Luo
President/Chief Executive Officer/Chief Scientific Officer/Director
Jack Zhang
Chief Financial Officer/Executive Vice President - Finance/Treasurer
William Peters
Executive Vice President/Director of Sales/Director of Marketing/Secretary
Jacob Liawatidewi
Executive Vice President
Rong Zhou
Lead Director/Independent Director
Richard Prins
Director
Diane Gerst
Independent Director
Gayle Deflin
Independent Director
Howard Lee
Independent Director
Floyd Petersen
Independent Director
Michael Zasloff
No Data
No Data
About AMPH
Amphastar Pharmaceuticals, Inc. is a bio-pharmaceutical company. The Company is primarily focused on developing, manufacturing, marketing and selling generic and injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient, or insulin API, products. It manufactures and sells over 20 products. It operates through two segments: finished pharmaceutical products and API products. It marketed products include Primatene Mist, Enoxaparin, Glucagon for Injection Emergency Kit, Naloxone and Other finished pharmaceutical products. Primatene Mist, an over-the-counter epinephrine inhalation product, is indicated for the temporary relief of mild symptoms of intermittent asthma. Enoxaparin is an injectable form of low molecular weight heparin that is used as an anticoagulant, which is indicated for multiple indications, including the prevention and treatment of deep vein thrombosis. Glucagon for injection is a difficult to manufacture injectable product.

Webull offers kinds of Amphastar Pharmaceuticals Inc stock information, including NASDAQ:AMPH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AMPH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AMPH stock methods without spending real money on the virtual paper trading platform.